Johnson & Johnson Announces 2-for-1 Stock Split and Dividend Increase of 12.5%

Apr 26, 2001, 01:00 ET from Johnson & Johnson

    NEW BRUNSWICK, N.J., April 26 /PRNewswire/ -- Johnson & Johnson
 (NYSE:   JNJ) today announced that the Board of Directors has declared a 2-for-1
 stock split and a 12.5% increase in the quarterly dividend rate.  This action
 was announced this morning at the Annual Shareowners Meeting in New Brunswick,
 NJ.
     "In recognition of our strong financial position, and our confidence in
 the future of the Corporation, the Board of Directors has voted to increase
 our dividend for the 39th consecutive year," said Ralph S. Larsen, Chairman
 and Chief Executive Officer of the Company.
     Adjusted for the stock split, the new dividend on an annual basis is
 $.72 compared to the previous rate of $.64.  The next quarterly dividend is
 payable on June 12, 2001 to shareowners of record as of May 22, 2001.
     Shareowners of record at the close of business on May 22, 2001 will be
 issued one additional share of Johnson & Johnson common stock for each share
 owned as of that date.  The Company anticipates that the additional shares
 resulting from the split will be issued in book-entry form on or about
 June 12, 2001.  Shareowners will be entitled to receive physical stock
 certificates upon request.
     Johnson & Johnson shares outstanding as of the close of the Company's
 first quarter on April 1, 2001, were approximately 1.4 billion on a diluted
 basis.  The last stock split announced by Johnson & Johnson was in 1996, when
 shares were split 2-for-1.
     On April 17, Johnson & Johnson announced sales and earnings for the first
 quarter of 2001.  Sales of $7.8 billion and net earnings of $1.5 billion
 increased by 6.5% and 14.2%, respectively, over first-quarter 2000 results.
     Johnson & Johnson, with approximately 99,200 employees, is the world's
 most comprehensive and broadly-based manufacturer of health care products, as
 well as a provider of related services, for the consumer, pharmaceutical and
 medical devices and diagnostics markets.  Johnson & Johnson has more than 190
 operating companies in 51 countries around the world, selling products in more
 than 175 countries.  For more information on Johnson & Johnson, please visit
 the company's website at http://www.jnj.com.
 
     (This press release contains "forward-looking statements" as defined in
 the Private Securities Litigation Reform Act of 1995.  These statements are
 based on current expectations of future events.  If underlying assumptions
 prove inaccurate or unknown risks or uncertainties materialize, actual results
 could vary materially from the Company's expectations and projections.  Risks
 and uncertainties include general industry conditions and competition;
 economic conditions, such as interest rate and currency exchange rate
 fluctuations; technological advances and patents attained by competitors;
 challenges inherent in new product development, including obtaining regulatory
 approvals; domestic and foreign health care reforms and governmental laws and
 regulations; and trends toward health care cost containment.  A further list
 and description of these risks, uncertainties and other factors can be found
 in Exhibit 99(b) of the Company's Annual Report on Form 10-K for the fiscal
 year ended December 31, 2000. Copies of this Form 10-K are available online at
 http://www.sec.gov or on request from the Company. The Company assumes no
 obligation to update any forward-looking statements as a result of new
 information or future events or developments.)
 
 

SOURCE Johnson & Johnson
    NEW BRUNSWICK, N.J., April 26 /PRNewswire/ -- Johnson & Johnson
 (NYSE:   JNJ) today announced that the Board of Directors has declared a 2-for-1
 stock split and a 12.5% increase in the quarterly dividend rate.  This action
 was announced this morning at the Annual Shareowners Meeting in New Brunswick,
 NJ.
     "In recognition of our strong financial position, and our confidence in
 the future of the Corporation, the Board of Directors has voted to increase
 our dividend for the 39th consecutive year," said Ralph S. Larsen, Chairman
 and Chief Executive Officer of the Company.
     Adjusted for the stock split, the new dividend on an annual basis is
 $.72 compared to the previous rate of $.64.  The next quarterly dividend is
 payable on June 12, 2001 to shareowners of record as of May 22, 2001.
     Shareowners of record at the close of business on May 22, 2001 will be
 issued one additional share of Johnson & Johnson common stock for each share
 owned as of that date.  The Company anticipates that the additional shares
 resulting from the split will be issued in book-entry form on or about
 June 12, 2001.  Shareowners will be entitled to receive physical stock
 certificates upon request.
     Johnson & Johnson shares outstanding as of the close of the Company's
 first quarter on April 1, 2001, were approximately 1.4 billion on a diluted
 basis.  The last stock split announced by Johnson & Johnson was in 1996, when
 shares were split 2-for-1.
     On April 17, Johnson & Johnson announced sales and earnings for the first
 quarter of 2001.  Sales of $7.8 billion and net earnings of $1.5 billion
 increased by 6.5% and 14.2%, respectively, over first-quarter 2000 results.
     Johnson & Johnson, with approximately 99,200 employees, is the world's
 most comprehensive and broadly-based manufacturer of health care products, as
 well as a provider of related services, for the consumer, pharmaceutical and
 medical devices and diagnostics markets.  Johnson & Johnson has more than 190
 operating companies in 51 countries around the world, selling products in more
 than 175 countries.  For more information on Johnson & Johnson, please visit
 the company's website at http://www.jnj.com.
 
     (This press release contains "forward-looking statements" as defined in
 the Private Securities Litigation Reform Act of 1995.  These statements are
 based on current expectations of future events.  If underlying assumptions
 prove inaccurate or unknown risks or uncertainties materialize, actual results
 could vary materially from the Company's expectations and projections.  Risks
 and uncertainties include general industry conditions and competition;
 economic conditions, such as interest rate and currency exchange rate
 fluctuations; technological advances and patents attained by competitors;
 challenges inherent in new product development, including obtaining regulatory
 approvals; domestic and foreign health care reforms and governmental laws and
 regulations; and trends toward health care cost containment.  A further list
 and description of these risks, uncertainties and other factors can be found
 in Exhibit 99(b) of the Company's Annual Report on Form 10-K for the fiscal
 year ended December 31, 2000. Copies of this Form 10-K are available online at
 http://www.sec.gov or on request from the Company. The Company assumes no
 obligation to update any forward-looking statements as a result of new
 information or future events or developments.)
 
 SOURCE  Johnson & Johnson